Treatment of melanoma;Therapie des melanoms

Deutsches Arzteblatt

Volumn 105, Issue 49, 2008, Pages 845-851

  Garbe, Claus ^a,e   Terheyden, Patrick ^b   Keilholz, Ulrich ^c   Kölbl, Oliver ^d   Hauschild, Axel ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c III Med Klin   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adjuvant therapy; Cancer treatment; Radiotherapy; Skin cancer; Surgery

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA2B INTERFERON; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; GEMCITABINE; HYDROXYUREA; INTERLEUKIN 2; LOMUSTINE; PACLITAXEL; PEGINTERFERON ALPHA2B; TEMOZOLOMIDE; TREOSULFAN; VINCRISTINE; VINDESINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; INCIDENCE; MELANOMA; PRACTICE GUIDELINE; SAFETY; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY;

EID: 57749185660     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2008.0845     Document Type: Article

References (25)

1. de Vries E, Bray FI, Coebergh JW et al.: Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-26.
2. Garbe C, Blum A: Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14: 280-90.
3. Bauer J, Garbe C: Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res 2003; 16: 297-306.
4. Wiecker TS, Luther H, Buettner P et al.: Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. Cancer 2003; 97: 628-38.
5. Miller AJ, Mihm MC, Jr: Melanoma. N Engl J Med 2006; 355: 51-65.
6. Balch CM, Buzaid AC, Soong SJ et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
7. Balch CM, Soong SJ, Gershenwald JE et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
8. Garbe C, Schadendorf D, Stolz W et al.: Kurzleitlinie - Malignes Melanom der Haut. JDDG 2008; 6: Supp 1: S20-6.
9. Garbe C, Hauschild A, Volkenandt M et al.: Evidence and interdisciplinary consensus-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007; 17: 393-9.
10. Garbe C, Hauschild A, Volkenandt M et al.: Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res 2008; 18: 61-7.
11. Garbe C, Hauschild A, Volkenandt M et al.: Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res 2008; 18: 152-60.
12. Hauschild A, Eiling S, Lischner S et al.: Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials. Hautarzt 2001; 52: 1003-10.
13. Breuninger H, Schaumburg-Lever G: Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. J Pathol 1988; 154: 167-71.
14. Breuninger H, Schlagenhauff B, Stroebel W et al.: Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. Am J Surg Pathol 1999; 23: 1493-8.
15. Morton DL,Wen DR,Wong JH et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
16. Gershenwald JE, Thompson W, Mansfield PF et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83.
17. Morton DL, Thompson JF, Cochran AJ et al.: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17.
18. Seegenschmiedt MH, Keilholz L, Pieritz A et al.: Lokal rezidiviertes und metastasiertes malignes Melanom. Langzeitergebnisse und Prognosefaktoren nach perkutaner Radiotherapie. Strahlenther Onkol 1999; 175: 450-7.
19. Burmeister BH, Mark SB, Burmeister E et al.: A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma - Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 2006; 81: 136-42.
20. Kirova YM, Chen J, Rabarijaona LI et al.: Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999; 9: 611-3.
21. Olivier KR, Schild SE, Morris CG et al.: A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007; 110: 1791-5.
22. Andrews DW, Scott CB, Sperduto PW et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-72.
23. Wheatley K, Ives N, Eggermont AM et al.: Interferon-alpha as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 2007; 25: 8526.
24. Hauschild A, Gogas H, Tarhini A et al.: Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112: 982-94.
25. Eigentler TK, Caroli UM, Radny P et al.: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 748-59.